Compare · VIR vs XBIT
VIR vs XBIT
Side-by-side comparison of Vir Biotechnology Inc. (VIR) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. VIR focuses on Biotechnology: Biological Products (No Diagnostic Substances), while XBIT focuses on Biotechnology: Pharmaceutical Preparations.
- VIR is the larger of the two at $2.08B, about 34.7x XBIT ($59.8M).
- VIR has been more active in the news (20 items in the past 4 weeks vs 7 for XBIT).
- VIR has more recent analyst coverage (19 ratings vs 0 for XBIT).
- Company
- Vir Biotechnology Inc.
- XBiotech Inc.
- Price
- -
- -
- Market cap
- $2.08B
- $59.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2015
- News (4w)
- 20
- 7
- Recent ratings
- 19
- 0
Vir Biotechnology Inc.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Latest VIR
- Vir Biotechnology Announces Pricing of Public Offering of Common Stock
- SEC Form 424B5 filed by Vir Biotechnology Inc.
- Vir Biotechnology Announces Proposed Public Offering
- SEC Form S-3ASR filed by Vir Biotechnology Inc.
- SEC Form SCHEDULE 13G filed by Vir Biotechnology Inc.
- Vir Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
- Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
- Amendment: SEC Form SCHEDULE 13D/A filed by Vir Biotechnology Inc.
- Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call
Latest XBIT
- SEC Form 10-Q filed by XBiotech Inc.
- SEC Form 4 filed by XBiotech Inc.
- SEC Form 3 filed by XBiotech Inc.
- Director Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)
- SEC Form 8-K filed by XBiotech Inc.
- XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
- XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
- SEC Form DEF 14A filed by XBiotech Inc.
- SEC Form 10-Q filed by XBiotech Inc.
- XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis